Company Announcement

Tuesday 12th April 2011
Melbourne, Australia and Baar, Switzerland

SCENESSE® (afamelanotide) data to be presented at global porphyria conference

Evaluation of SCENESSE® as porphyria preventative being presented at biennial Porphyrins & Porphyrias conference

Clinuvel Pharmaceuticals Limited (**ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY**) today announced that data evaluating the safety and efficacy of SCENESSE® (afamelanotide) as a photoprotective drug in the rare disease erythropoietic protoporphyria (EPP) will be presented at the **'Porphyrins & Porphyrias 2011' conference on April 13 in Cardiff, Wales.**

Porphyrins & Porphyrias 2011
The biennial forum brings together around 200 international experts in porphyrias. The data presented will be part of an evaluation of the clinical experience gained by physicians and patients who participated in Phase II (CUV010) and Phase III (CUV017) EPP studies and compassionate programs initiated by Clinuvel.

Two satellite porphyria meetings on April 14, one for British dermatologists and the other for the porphyria patient population, will also address clinical experiences of SCENESSE® as a photoprotective therapy in EPP.

Erythropoietic protoporphyria (EPP)
EPP is characterised by severe phototoxicity of the skin resulting in intolerable pain, swelling, and scarring, usually of the exposed areas such as the face, hands and feet. EPP patients are often forced to lead an indoors existence, severely affecting their quality of life. Approximately 10,000 people globally are affected by EPP, including an estimated 400 in Britain.

Clinical studies of SCENESSE® to date have shown the drug to be able to reduce the severity and number of phototoxic reactions in EPP while being well tolerated in this patient group.

"The opinions of expert physicians treating EPP and their patients' response have been the two main factors supporting Clinuvel's decision to initiate and advance the program of SCENESSE® in EPP," Clinuvel's CEO, Dr Philippe Wolgen said. "With frequent feedback of both groups, we have learned over recent years how the drug is able to address the dermal symptoms and help patients to lead a normal outdoor life. Naturally, our team is curious to learn of the latest experiences at this forum."

Clinuvel is a sponsor of the 'Porphyrins & Porphyrias 2011' conference which runs from April 10-14. The company has published an EPP patient resource sheet to coincide with the conference which can be downloaded from http://www.clinuvel.com/erythropoietic-protoporphyria.

- End -

About SCENESSE® (afamelanotide)
SCENESSE® is a first-in-class therapeutic being developed by Clinuvel, with the generic name (or INN) afamelanotide. An analogue of α-MSH, afamelanotide is a linear peptide which activates eumelanin of the skin, the dark pigment which is known to provide photoprotective properties (offering skin protection against light and UV radiation). SCENESSE® is administered underneath the skin as a dissolvable implant approximately the size of a grain of rice. For more information on SCENESSE® go to http://www.clinuvel.com/scenesse.

SCENESSE® is a registered trademark of Clinuvel Pharmaceuticals Ltd.

About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Ltd is a leading and innovative Australian company focused on the development of SCENESSE® (afamelanotide), its proprietary first-in-class photoprotective drug. Clinuvel has identified a number of groups of patients with a clinical need for photoprotection and one with a need for repigmentation therapy. Currently, Clinuvel is in its final stages to complete testing of SCENESSE® in Phase II and III trials in Australia, Europe and the United States. Clinuvel's ongoing focus is to demonstrate the safety and efficacy of SCENESSE®. Pending positive clinical results, Clinuvel aims to file SCENESSE® for its first market approval for the orphan indication porphyria (EPP).

For more information contact:

Australia:	Clinuvel Pharmaceuticals Limited,	T: +61 3 9660 4900
Europe:	Clinuvel AG,	T: +41 41 767 45 45
E:		investorrelations@clinuvel.com

Clinuvel is an Australian biopharmaceutical company focussed on developing its photoprotective drug, SCENESSE® (afamelanotide) for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for SCENESSE® can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for SCENESSE® is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

Level 11 / 330 Collins Street
Melbourne, Victoria 3000
Australia

T +61 3 9660 4900
F +61 3 9660 4999

www.clinuvel.com